Close Menu

NEW YORK – The US Food and Drug Administration announced Thursday that Cepheid's test for SARS-CoV-2, influenza, and respiratory syncytial virus received Emergency Use Authorization for use in high and moderate complexity laboratories and at the point of care. 

The rapid multiplex RT-PCR test detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus RNA and can provide results in 35 minutes. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.